RU2018127882A3 - - Google Patents

Download PDF

Info

Publication number
RU2018127882A3
RU2018127882A3 RU2018127882A RU2018127882A RU2018127882A3 RU 2018127882 A3 RU2018127882 A3 RU 2018127882A3 RU 2018127882 A RU2018127882 A RU 2018127882A RU 2018127882 A RU2018127882 A RU 2018127882A RU 2018127882 A3 RU2018127882 A3 RU 2018127882A3
Authority
RU
Russia
Application number
RU2018127882A
Other languages
Russian (ru)
Other versions
RU2747877C2 (ru
RU2018127882A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018127882A publication Critical patent/RU2018127882A/ru
Publication of RU2018127882A3 publication Critical patent/RU2018127882A3/ru
Application granted granted Critical
Publication of RU2747877C2 publication Critical patent/RU2747877C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/485Epidermal growth factor [EGF], i.e. urogastrone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
RU2018127882A 2016-01-13 2017-01-13 Аналоги эфр(а) с заместителями - жирными кислотами RU2747877C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2016070791 2016-01-13
CNPCT/CN2016/070791 2016-01-13
CNPCT/CN2016/076580 2016-03-17
CN2016076580 2016-03-17
EP16195965.5 2016-10-27
EP16195965 2016-10-27
PCT/EP2017/050668 WO2017121850A1 (en) 2016-01-13 2017-01-13 Egf(a) analogues with fatty acid substituents

Publications (3)

Publication Number Publication Date
RU2018127882A RU2018127882A (ru) 2020-02-13
RU2018127882A3 true RU2018127882A3 (enExample) 2020-06-19
RU2747877C2 RU2747877C2 (ru) 2021-05-17

Family

ID=57868232

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018127882A RU2747877C2 (ru) 2016-01-13 2017-01-13 Аналоги эфр(а) с заместителями - жирными кислотами

Country Status (26)

Country Link
US (2) US10822385B2 (enExample)
EP (1) EP3402811B1 (enExample)
JP (2) JP6797926B2 (enExample)
KR (1) KR102417487B1 (enExample)
CN (1) CN108473550B (enExample)
AU (1) AU2017207862B2 (enExample)
BR (1) BR112018013820A2 (enExample)
CA (1) CA3010756A1 (enExample)
CL (1) CL2018001868A1 (enExample)
CO (1) CO2018007440A2 (enExample)
DK (1) DK3402811T3 (enExample)
ES (1) ES2916998T3 (enExample)
HR (1) HRP20220720T1 (enExample)
HU (1) HUE058647T2 (enExample)
IL (1) IL260043A (enExample)
LT (1) LT3402811T (enExample)
MX (1) MX2018008681A (enExample)
MY (1) MY195199A (enExample)
PE (1) PE20181376A1 (enExample)
PH (1) PH12018501502A1 (enExample)
PL (1) PL3402811T3 (enExample)
RS (1) RS63298B1 (enExample)
RU (1) RU2747877C2 (enExample)
SA (1) SA518391996B1 (enExample)
SI (1) SI3402811T1 (enExample)
WO (1) WO2017121850A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE070444T2 (hu) 2016-01-13 2025-06-28 Gruenenthal Gmbh 3-((hetero-)aril)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-dekán-származékok
KR20180097733A (ko) 2016-01-13 2018-08-31 그뤼넨탈 게엠베하 3-(카복시메틸)-8-아미노-2-옥소-1,3-디아자-스피로-[4.5]-데칸 유도체
AU2017206909B2 (en) 2016-01-13 2020-07-09 Grünenthal GmbH 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
TWI654181B (zh) 2016-01-13 2019-03-21 歌林達有限公司 8-胺基-2-側氧基-1,3-二氮-螺-[4.5]-癸烷衍生物
MX2018008681A (es) 2016-01-13 2018-09-17 Novo Nordisk As Analogos del dominio a similar al factor de crecimiento epidermico (egf(a)) con sustituyentes de acidos grasos.
US11130794B2 (en) 2017-07-19 2021-09-28 Novo Nordisk A/S Bifunctional compounds
MA49617A (fr) * 2017-07-19 2020-05-27 Novo Nordisk As Analogues d'egf(a), préparation, formulations et utilisations associées
WO2019023295A1 (en) * 2017-07-27 2019-01-31 Saint Louis University Fatty acid modified human epidermal growth factor
JOP20190150A1 (ar) 2018-06-21 2019-12-21 Merck Sharp & Dohme مركبات مناهضة لـ pcsk9
TW202028229A (zh) * 2018-10-05 2020-08-01 丹麥商諾佛 儂迪克股份有限公司 包含胰島素肽及egf(a)肽之雙功能化合物
CA3131997A1 (en) 2019-03-22 2020-10-01 3M Innovative Properties Company Fall-protection system with monitoring system
CN110357969B (zh) * 2019-05-27 2022-03-08 北京志道生物科技有限公司 一种GLP1-EGFa异源二聚体蛋白、功能及方法
BR112022000529A2 (pt) 2019-08-07 2022-03-03 Novo Nordisk As Composição farmacêutica
PE20221458A1 (es) 2019-11-07 2022-09-21 Novo Nordisk As Composiciones solidas que comprenden un inhibidor de pcsk9 y una sal de acido n-(8-(2-hidroxibenzoil)amino)caprilico
EP4556431A3 (en) 2021-07-02 2025-08-13 3M Innovative Properties Co. Aerial lift interlocked with fall-protection safety apparatus
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
WO2007018619A2 (en) 2005-07-29 2007-02-15 Amprotein Corporation Chimeric therapeutic agents
EP2178910B1 (en) 2007-08-15 2014-10-08 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
WO2009131740A2 (en) * 2008-04-23 2009-10-29 Amgen Inc. Neutralizing proprotein convertase subtilisin kexin type 9 (pcsk9) variants and uses thereof
WO2009143633A1 (en) 2008-05-30 2009-12-03 Institut De Recherches Cliniques De Montreal Pcsk9 inhibitors and methods of use thereof
TWI445716B (zh) * 2008-09-12 2014-07-21 Rinat Neuroscience Corp Pcsk9拮抗劑類
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
WO2012017774A1 (ja) * 2010-08-02 2012-02-09 日本電気株式会社 偏光子及び発光装置
CN102153652A (zh) 2010-12-10 2011-08-17 浙江大学 一种融合蛋白的表达方法及用途
US20140011728A1 (en) 2011-02-15 2014-01-09 Novo Nordisk A/S Long-acting il-1 receptor antagonists
JP2014519848A (ja) * 2011-06-20 2014-08-21 ジェネンテック, インコーポレイテッド Pcsk9結合ポリペプチドと使用方法
TWI596110B (zh) * 2011-09-23 2017-08-21 諾佛 儂迪克股份有限公司 新穎升糖素類似物
TW201315742A (zh) 2011-09-26 2013-04-16 Novartis Ag 治療代謝病症之雙功能蛋白質
US20140357838A1 (en) * 2011-12-21 2014-12-04 Novo Nordisk A/S N-Terminally Modified Insulin Derivatives
CN112142855A (zh) 2012-05-18 2020-12-29 爱德迪安(北京)生物技术有限公司 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
AR092076A1 (es) 2012-08-22 2015-03-18 Lilly Co Eli Proteinas homodimericas
BR112015004734A2 (pt) 2012-09-07 2017-11-21 Sanofi Sa proteínas de fusão para tratar uma síndrome metabólica
PL2986313T3 (pl) * 2013-04-18 2019-12-31 Novo Nordisk A/S Stabilni, dłużej działający współagoniści receptora glp-1/glukagonu do zastosowań medycznych
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
EP3107937A4 (en) 2014-02-21 2017-11-15 MedImmune, LLC Anti-pcsk9~glp-1 fusions and methods for use
US10570184B2 (en) * 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
CN104558198A (zh) 2014-07-25 2015-04-29 成都贝爱特生物科技有限公司 GLP-1类似物和amylin类似物的融合蛋白制备及其用途
EP3271379A4 (en) * 2015-03-19 2018-08-01 Institut de Cardiologie de Montréal Grp94 derived polypeptides for inhibiting pcsk9 and methods of use
CN105367884A (zh) 2015-11-02 2016-03-02 陈薇 一种绝缘耐火抗辐射的屏蔽电缆材料及其制备方法
MX2018008681A (es) 2016-01-13 2018-09-17 Novo Nordisk As Analogos del dominio a similar al factor de crecimiento epidermico (egf(a)) con sustituyentes de acidos grasos.
MA49617A (fr) 2017-07-19 2020-05-27 Novo Nordisk As Analogues d'egf(a), préparation, formulations et utilisations associées
US11130794B2 (en) 2017-07-19 2021-09-28 Novo Nordisk A/S Bifunctional compounds

Also Published As

Publication number Publication date
LT3402811T (lt) 2022-06-10
KR20180100177A (ko) 2018-09-07
MX2018008681A (es) 2018-09-17
US20190016768A1 (en) 2019-01-17
EP3402811A1 (en) 2018-11-21
US20200407409A1 (en) 2020-12-31
JP2019505521A (ja) 2019-02-28
SI3402811T1 (sl) 2022-06-30
PL3402811T3 (pl) 2022-07-11
CA3010756A1 (en) 2017-07-20
HUE058647T2 (hu) 2022-09-28
CO2018007440A2 (es) 2018-09-28
CN108473550A (zh) 2018-08-31
WO2017121850A1 (en) 2017-07-20
HRP20220720T1 (hr) 2022-09-30
RU2747877C2 (ru) 2021-05-17
CL2018001868A1 (es) 2018-08-31
JP6797926B2 (ja) 2020-12-09
BR112018013820A2 (pt) 2018-12-11
IL260043A (en) 2018-07-31
EP3402811B1 (en) 2022-03-30
RS63298B1 (sr) 2022-07-29
US10822385B2 (en) 2020-11-03
ES2916998T3 (es) 2022-07-06
AU2017207862B2 (en) 2020-12-17
DK3402811T3 (da) 2022-06-13
KR102417487B1 (ko) 2022-07-06
RU2018127882A (ru) 2020-02-13
PE20181376A1 (es) 2018-09-05
AU2017207862A1 (en) 2018-07-05
SA518391996B1 (ar) 2021-07-14
JP2021035989A (ja) 2021-03-04
PH12018501502A1 (en) 2019-03-25
CN108473550B (zh) 2022-11-22
MY195199A (en) 2023-01-11

Similar Documents

Publication Publication Date Title
BR112018068177A2 (enExample)
RU2018127882A3 (enExample)
BR112019001429A2 (enExample)
BR112019000402A2 (enExample)
BR112019008315A2 (enExample)
BR112018004966A2 (enExample)
BR102016018018A2 (enExample)
CN303536542S (enExample)
CN303589965S (enExample)
CN303536548S (enExample)
CN303673412S (enExample)
CN303536593S (enExample)
CN303655397S (enExample)
CN303536622S (enExample)
CN303536547S (enExample)
CN303537263S (enExample)
CN303646961S (enExample)
CN303641694S (enExample)
CN303640127S (enExample)
CN303634893S (enExample)
CN303537289S (enExample)
CN303631348S (enExample)
CN303625310S (enExample)
CN303618704S (enExample)
CN303536579S (enExample)